Japanese clear Novartis' Gilenya, Vertex's hep C drug

Japanese regulators approved two important new drugs: Novartis's Gilenya, the first oral multiple sclerosis treatment, and Vertex Pharmaceuticals's Telavic, the hepatitis C treatment sold as Incivek in the U.S. and developed for Japan in partnership with Mitsubishi Tanabe Pharma. Novartis release | Release